Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Account Payables
Amounts the company owes suppliers for goods and services received.
Sagimet Biosciences Inc.NASDAQ: SGMT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 28.5% from a year ago
Account payables stood at $2.3M at the end of Q1 FY2026, down 28.5% from a year earlier and up 75.9% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Account payables amounted to 2.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -28.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.31M USD
- Year-over-year change
- -8.1%
- 4-year CAGR
- +14.5%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.31M | -8.1% |
| FY2024 | 2024-12-31 | 1.43M | +666.1% |
| FY2023 | 2023-12-31 | 186K | -83.5% |
| FY2022 | 2022-12-31 | 1.13M | +47.8% |
| FY2021 | 2021-12-31 | 761K | — |
Account Payables vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 account payables of $2.3M is the 8th highest of the 11 companies compared; the peer median is $3.12M.
- Its year-over-year change of -28.5% is the 9th highest of 11, against a peer median of +15.6%.
- Account payables amounts to 2.1% of total assets for SGMT, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.45B | +110780.3% | -21.2% | 0.7% | |
| Mar 2026 | $9.45M | +27.9% | +71.8% | 3.5% | |
| Mar 2026 | $5.08M | -8.8% | +50.2% | 4.6% | |
| Mar 2026 | $4.09M | -33.8% | -17.2% | 1.7% | |
| Mar 2026 | $3.32M | -18.5% | -7.6% | 1.5% | |
| Mar 2026 | $2.93M | +33.9% | -27.4% | 0.9% | |
| Mar 2026 | $2.72M | +3.4% | +25.0% | 1.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $2.3M | -28.5% | +5.2% | 2.1% |
ZURAZura Bio Limited | Mar 2026 | $2.08M | +66.8% | -14.0% | 0.9% |
| Mar 2026 | $1.13M | +29.0% | -22.3% | 0.5% | |
| Mar 2026 | $833K | -49.7% | -19.5% | 2.5% | |
| Peer median (excluding SGMT) | $3.12M | +15.6% | -15.6% | 1.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.